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Added value of positron emission tomography imaging in the
surgical treatment of colorectal liver metastases
Bastiaan Wieringa, Eddy M.M. Adangb, Joost R.M. van der Sijpe,
Rudi M. Roumenh, Koert P. de Jongi, Emile F.I. Comansf, Jan Pruimj,
Helena M. Dekkerc, Theo J.M. Ruersg, Paul F.M. Krabbeb and Wim J.G. Oyend
Objective [F-18]-Fluorodeoxyglucose-positron emission
tomography (FDG-PET) is used increasingly in the work-up
to surgery for patients with potentially resectable colorectal
liver metastases. This study evaluates the clinical
effectiveness, impact on health care resources and
cost-effectiveness of adding FDG-PET to the diagnostic
algorithm alongside a randomized clinical trial from a
health care perspective.
Methods In a randomized clinical trial, the net monetary
benefit (NMB) of FDG-PET added to conventional
diagnostic work-up (CWU) was determined in patients with
colorectal liver metastases. Seventy-five patients were
included in each arm. Change in clinical management, futile
laparotomies, preoperative findings and all relevant health
care consumption were prospectively documented during
3 years. To assess health-related quality of life European
Quality of Life-5 Dimensions was administered at the time
of randomization, 3 and 6 weeks postoperatively, and every
3 months postoperatively for 3 years. Quality-adjusted life
years (QALYs) were calculated based on European Quality
of Life-5 Dimensions outcomes.
Results In adding FDG-PET, diagnostic performance
increased and futile laparotomies were reduced by 38%.
Both health-related quality of life and QALYs showed no
significant difference between the CWU and PET groups.
For CWU and PET groups costs were h92836 and h81776,
respectively, accumulated in 3 years after randomization.
NMB ranged from h1004 to h11 060 depending on the
monetary value given to a QALY. When costs for
chemotherapy were disregarded, costs amounted to
h15 874 for CWU and h18 664 for PET group.
Conclusion Additional costs of FDG-PET in the diagnostic
work-up of patients with potentially resectable colorectal
liver metastases were compensated by a reduction in
futile laparotomies. The NMB analysis showed savings
over a relevant range of willingness to pay for a QALY.
Nucl Med Commun 31:938–944 c 2010 Wolters Kluwer
Health | Lippincott Williams & Wilkins.
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Introduction
Survival of patients with colorectal cancer strongly
depends on the development of distant metastases. Ap-
proximately 50–60% of the patients with primary colo-
rectal tumour develop hepatic metastases [1,2]. These
metastases are either identified at the time of diagnosis
of the primary tumour (synchronous metastases) or
during follow-up (metachronous metastases). Hepatic
resection is the only curative therapy for a selected group
of patients with colorectal liver metastases. For surgical
treatment stringent selection criteria apply because no
survival benefit is found if residual disease remains after
hepatectomy. After resection, 5-year survival rates have
been reported between 35 and 45% [3–6], compared with
less than 15% in patients with unresectable colorectal
liver metastases [7,8]. In up to 50% of the patients who
undergo curative liver resection, recurrent disease is
detected in the first year after surgery [9–12]. These
figures strongly suggest that both before and during surgery
minimal residual metastatic disease remains undetected.
Therefore, a critical evaluation of preoperative and intra-
operative diagnostic modalities is necessary with regard to
both efficacy and cost-effectiveness.
Positron emission tomography (PET) with [F-18]-fluoro-
deoxyglucose (FDG) is a sensitive diagnostic tool for
displaying both primary colorectal cancer and its metastases
[13,14]. As a promising and upcoming modality for the
evaluation of recurrent colorectal disease, FDG-PET imag-
ing is based on metabolic changes instead of anatomical and
structural changes, as is the case for computed tomography
(CT) or magnetic resonance imaging (MRI). As such,
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FDG-PET has the potential to show tumour activity ahead
of CT or magnetic resonance imaging [15]. Further-
more, data suggest that additional FDG-PET results in
a change in clinical management of up to 30% during the
diagnostic work-up of patients eligible for surgical treat-
ment of metastatic colorectal cancer [16–18].
The added value of the integration of FDG-PET in the
diagnostic algorithm for surgical treatment of colorectal
liver metastases has yet to be determined, despite
increased sensitivity and specificity of FDG-PET as
reported in the literature. Several studies have examined
the cost-effectiveness of the FDG-PET in a number of
diagnostic scenarios through modelling [19–21], whereas
others have emphasized the cost-effectiveness of hepatic
resection [22,23]. These studies attempt to show that
FDG-PET is cost-effective in colorectal metastatic
disease when added to conventional work-up (CWU),
although strong data have yet to emerge. To increase the
level of evidence of the value of adding FDG-PET to the
CWU, a randomized controlled study [24] was con-
ducted. Alongside this study the costs from a healthcare




Patients were enrolled in a randomized, controlled, multi-
centre trial between May 2002 and February 2006.
Eligible patients were required to have a history of
histologically documented colorectal cancer treated with
adequate surgical resection (tumour-free resection mar-
gins), suspicion of up to four potentially resectable
colorectal liver metastases without evidence of extra-
hepatic metastatic disease (with exception of a maximum
of two resectable lung metastases) on contrast-enhanced
CTscan of the abdomen, pelvis and chest and no signs of
recurrent or second colorectal carcinoma.
Randomization was done at the central trial office. When
randomized to the conventional arm the patients were
scheduled for hepatic surgery without any further diag-
nostic procedures. When randomized to the experimental
arm, additional whole-body FDG-PET scanning was per-
formed, generally within 2 weeks, and the results of both
CT imaging and FDG-PET scan were again reported at a
multidisciplinary oncology meeting. A joint assessment of
all available data was made to review the clinical
information and diagnostic imaging on a case-by-case basis.
For more details about study protocol, eligibility and
standardized follow-up we refer to a recent paper by this
group [24]. After hepatic resection all patients were fol-
lowed prospectively at regular predetermined intervals of
3 months for the first 3 years after intervention. The
study was approved by the institutional ethics review
boards of all participating centres and all patients pro-
vided written informed consent.
Outcome measures and data collection
Clinical outcomes
Case record forms were used to collect data during the
trial period. The standardized forms were used to record
preoperative and demographic data, all diagnostic and
perioperative information, essential costs during hospital
stay and all follow-up data, including additional diagnos-
tics for 3 years after hepatic resection.
Futile laparotomies were defined as any laparotomy that
did not result in complete removal of the tumour, hepatic
or extra-hepatic, which revealed benign disease at laparo-
tomy or at histopathology, or that did not result in a disease-
free survival period longer than 6 months. Disease-free
and overall survival was assessed from the day of
randomization.
Health-state values
Overall health-related quality of life (HRQoL) appraisals
in different states of health can be expressed as a single
metric number, often referred to as values or utilities.
These health-state values are combined with survival
data to compute quality-adjusted life-years (QALYs). One
QALY equals 1 year in full health.
HRQoL during the first 3 years of follow-up was
measured with the EQ-5D (European Quality of Life-5
Dimensions) [25–27]. Health status on the EQ-5D was
described according to five attributes: mobility, self-care,
usual activities, pain/discomfort and anxiety/depression;
each of these attributes consists of three levels: no
problems, some problems or severe problems. The
HRQoL of both the groups was evaluated at time of
randomization, 3 and 6 weeks after surgery, and subse-
quently every 3 months for 3 years.
Treatment costs
All direct health-care-related costs during the first 3 years
after inclusion were prospectively documented in the
case record forms, including inpatient and outpatient
costs, such as the surgical technique used, the amount of
blood loss, total operation time, chemotherapy, secondary
operations, complications (e.g. ileus, wound infection,
biloma, pneumonia), outpatient visits, diagnostic tests.
For prices, the actual, true unit costs were used. Unit
costs were built up on personnel, material and capacity
cost. For standard units of care, like intensive care unit
days, in hospital days, out-patient visits etc., standard
cost prices as stated in the Dutch manual for costing
research by Oosterbrink et al. [28] indexed using the
consumer price index to 2007 prices, were used (www.
statline.nl). Overhead was defined as 35% of the accumu-
lated direct costs in line with the Dutch guidelines for
costing research (Oostenbrink et al. [28]).
Excluding chemotherapy costs seems obvious when deal-
ing with a diagnostic-driven trial, but given the influence
on outcomes in disease-free and overall survival, both
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evaluations were taken into account. This underlines the
fact that considering only the diagnostic channel provides
intermediate outcomes with potentially biased results
and potentially different policy decisions about adding
FDG-PET technology to the benefit package. Whether
and under what conditions FDG-PET is an efficient
modality for patients adhering to the inclusion criteria of
this trial are therefore described in a transparent way
presenting both scenarios, the diagnostic channel only
and the diagnostic channel plus the clinical pathway up to
3 years. Costs and effectiveness have been discounted at
a 3% rate for the duration of the study, that is, 3 years.
The perspective of accumulated costs in this study is that
of the Dutch national health system.
Efficiency analysis
Cost–utility analysis was conducted from a health-care
perspective. The efficiency of FDG-PET compared with
CWU is expressed as the net monetary benefit (NMB).
The NMB is an outcome presented in money terms that
subtracts the net cost from the net effect between FDG-
PET and CWU. The net costs are measured as the
difference in costs between FDG-PET and CWU. The
net effect is measured as the difference in QALYs
between FDG-PET and CWU multiplied by a monetary
value given to a QALY. The decision rule states that when
the NMB is positive, FDG-PET is cost-effective com-
pared with CWU. For the Netherlands the range for
‘willingness to pay for a QALY’ is based on a report by the
Council for Public Health and Health Care (Raad voor
Volksgezondheid en Zorg), an advisory board to the
Ministry of health, titled ‘Duurzame en Zinnige zorg,
2006’ and ranges from h10 000–h80 000 depending on the
burden of illness [29].
Furthermore, a bootstrap procedure was performed to
provide an estimate of the uncertainty surrounding the
incremental cost-effectiveness ratio (ICER) [30]. Boot-
strapping is a statistical procedure that, for example, 1000
times resamples an actual measured point of additional
costs and additional QALY with replacement from the
original sample. This method reduces the chance that
outliers significantly influence the cost–utility analysis
with extra health care consumption in the nominator and
QALYs gained in the denominator. The cost-effectiveness
plane visualizes the results of the bootstrap procedure
with effects on the x-axis and costs on the y-axis. This is
presented in a cost-effectiveness plane in which FDG-
PET can be placed, where every point represents an
estimated ICER. An ICER is the ratio of the change in
costs of a therapeutic intervention (compared with the
alternative) to the change in effects of the intervention.
Sensitivity analysis
To show the influence of a more intensive use, that is, a
higher occupancy rate, of the PET, possibly resulting in a
lower unit cost for each scan, a sensitivity analysis varying
the occupancy rate of the PET scanner was done.
Statistical analysis
For the difference between groups in costs and clinical
outcomes, Fisher’s exact test (two-sided) was used for
categorical data and t-tests for continuous data. Differ-
ences in survival were analyzed with the log-rank test. All
statistical analyses were done with the SPSS statistical
software (version 16.0, SPSS Inc., Chicago, Illinois, USA)




There were no baseline differences between both diag-
nostic work-up modalities (Table 1). Additional FDG-PET
findings resulted in the cancellation of planned resection of
the suspected liver metastases in five patients. Follow-up of
these cases showed that FDG-PET correctly predicted
benign disease in two patients and unresectable extra-
hepatic disease in three patients. Therefore, a total of 75
patients in the conventional arm without FDG-PETand 70
patients in the experimental arm with FDG-PET under-
went laparotomy (Table 2). During laparotomy, 17 (23%)
patients in the conventional arm and seven (9%) patients
in the experimental arm either showed significant addi-
tional metastatic disease precluding any further curative
surgical treatment or showed benign disease, both of which
has led to futile laparotomy (P=0.043).
In addition, follow-up showed disease recurrence within 6
months after surgical treatment in 16 and 13 patients in
the conventional and experimental groups, respectively.
As a result a significantly larger proportion of patients
underwent futile laparotomy in the control arm without
FDG-PET (45%) than in the experimental arm with
Table 1 Demographic data
Control arm (n=75) Experimental arm (n=70)
Age in years (range) 62.9 (37.9–79.9) 61.8 (32.8–78.1)





< 12 months 29 32
Z12 months 46 38
Number of hepatic tumoursa
1 41 40
>1 34 30
Size of greatest hepatic tumoura
< 50mm 60 54
>50mm 15 16
CEA preoperatively
< 200 ng/ml 75 70
Z200 ng/ml — —
CEA, carcinoembryonic antigen.
No significant statistical differences were found among the groups.
pN0, no nodal metastases in primary tumour, according to the Tumor, Node,
Metastasis (TNM) classification.
pNZ 1, one or more nodal metastases in primary tumour, according to the TNM
classification.
aAs preoperatively predicted on computed tomography, at the time of
randomization.
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FDG-PET (28%; P=0.042). The relative risk reduction
was 38% [95% confidence interval (CI): 4–60%]. Futile
laparotomy was not related to demographic differences or
prognostic factors, as reported elsewhere [24].
Health-state values and quality-adjusted life-years
The calculated health-state values were based on 73
patients in the CWU group (two patients did not return
any EQ-5D form) and 75 patients in the FDG-PET
group. During the follow-up in the first 3 years the
health-state values were not different for the two study
groups (Fig. 1). As 3-year overall survival seemed to be
almost identical for the two groups (65.8% for CWU and
61.3% for PET group), QALYs accumulated over the 3-
year follow-up period were not significantly different. For
the CWU group 1.78 QALYs were generated, whereas for
the PET group, QALYs of 1.67 were generated (mean
difference 0.10, 95% CI: – 0.19–0.39).
Cost analysis
The different costs over several diagnostic and treatment
options are presented in Table 3. The cost for surgery
were standardized to the cost for a 3-h OR (operation
room) session, without radio-frequency ablation (which
would raise costs with 1950 euros). Overall, after com-
paring the diagnostic strategies, the average total costs
were lower in the PET group (Table 2). Three years after
randomization the mean costs for the CWU and PET
groups were h 92 836 (range: h7516–h290 308) and
h81 776 (range: h6087–h341 012), respectively. When
the costs for chemotherapy were not taken into account,
the mean costs for the CWU group were h15 874 (range:
h5974–h34 143) versus h18 664 (range: h1984–h87 930)
for the PET group.
Economic analysis
The NMB (with 95% CIs) shows a decline (Fig. 2). This
decline can be explained by the fact that as the
willingness to pay for a QALY increases, more weight is
added to the slightly (insignificant) negative QALY effect
in the FDG-PET group.
Results of the bootstrap procedure are shown in the cost-
effectiveness plane (Fig. 3), in which most outcomes lie
beneath the x-axis, meaning that additional FDG-PET
is more likely to save money than to lose money over a
period of 3 years (given the indecisive effect). In a second
scenario when the bootstrap procedure was performed
over the data generated without chemotherapy, it is
shown that the inclusion of FDG-PET results in a less
favourable and more costly strategy (Fig. 4). Every point
in this cost-effectiveness plane represents an estimated
ICER derived from the bootstrap procedure expressed as
cost for each QALY gained.
Sensitivity analysis
Sensitivity analysis varying the occupancy rate of the PET
scanner (Table 4) showed that 1200 PETscans per scanner
per year (with 260 days for clinical use, thus 4.6 PETs per
day) would result in a unit cost of h987 per PET. If the
PET scanner could be used at a higher occupancy rate
these costs would decrease. For instance, with 10 scans a
day, the unit costs would become h759. However, this
strategy does not result in either a statistically significant
advantage in costs or in NMB for the PET group.
Table 2 Means of the costs (h) and difference of the mean and the QALYs in first 3 years after randomization for the two treatment arms:
CWU and CWU with additional FDG-PET
CWU (range) PET (range) Mean difference (95% CI interval)
Total cost 92836 (7516–290308) 81776 (6087–341012) 11060 (–16 830/38 949)
Cost without chemotherapy 15 874 (5974–34143) 18 664 (1984–87930) – 2790 ( – 6343/762)
Total cost of first hospital stay 10 429 (3671–24 420) 11770 (401–64 982) – 1341 ( – 4006/1322)
Total cost of diagnostics 1929 (253–4827) 2529 (401–64 982) – 600 ( – 925/276)
Total cost of outpatient visits 1061 (83 2008) 984 (84–1841) 77 ( – 61/215)
Total cost of additional hospital stay(s) 2455 (196–5544) 3380 (335 –21 037) – 925 ( – 1755/95)
QALYs in 3 years 1.78 (0.30–2.76) 1.68 (0.10–2.76) 0.10 (–0.19/0.39)

































80 100 120 140
CT CT + PET
Overall value of patients’ health in the first 3 years after randomization,
as calculated by the European Quality of Life-5 Dimensions values.
Area under the curve can be interpreted as number of quality-adjusted
life-years. CT, computed tomography; HRQoL, health-related quality of
life, PET, positron emission tomography.
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Discussion
This study shows that the addition of FDG-PET to CWU
in the diagnostic work-up for patients with potentially
resectable colorectal liver metastases results in a better
selection of patients for surgical intervention, and thus in
avoiding futile laparotomies. When considering a follow-
up period of 3 years and including all health care costs
accumulated in these years, the addition of FDG-PET
remained favourable, and resulted in an expected NMB
of up to h11 060, depending on the willingness to pay for
a QALY gained. However, conclusions about these
findings should be made with caution as statistical
significance could not be established. This leads to the
conclusion that the introduction of FDG-PET might be a
potentially cost-efficient diagnostic modality in the
diagnostic work-up of these patients.
Our findings are in line with earlier nonrandomized
studies on the use of FDG-PET in patients with
colorectal liver metastases [13,15,17,18]. Bipat et al.
[13] showed that FDG-PET had higher sensitivity for
the detection of liver metastases compared with other
imaging modalities. Identical observations were made for
the detection of extrahepatic disease [18].
In this study, 14 patients (18.7%) in the control arm
underwent futile laparotomy because of liver disease
Table 3 Actual cost of diagnostic, therapy and hospital stay
CT scan MRI Ultrasound
Chest





Costs of diagnostics, hospital days, intensive care treatment, outpatients visits (h)
Capacity 67.55 143.41 3.33 1.78 663.26 28.72
Personnel 56.51 60.10 41.82 16.49 67.98 100.52
Overhead 43.42 71.23 15.80 6.40 255.93 45.24
Total 167.48 274.74 60.95 24.67 987.17 174.48 107.28 490.12 1692.91

















Per therapy 1393.12 13 267.52 13 087.48 1820.45 5828.59
Per week 1393.12 1895.36 1869.64 606.82 1942.86
Overhead 487.60 663.38 654.37 312.38 680.11
Total/week 1880.72 2558.74 2524.01 819.20 2622.87
5FU, 5-fluorouracil; CT, computed tomography; LV, leucovorin; MRI, magnetic resonance imaging; OR, operation room; PET, positron emission tomography,
RFA, radiofrequency ablation.
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Cost-effectiveness plane of additional positron emission tomography
(PET), from a health care perspective. QALY, quality-adjusted life-years.
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being too extensive at laparotomy or the detection of
extrahepatic disease (data not shown). The outcome is
comparable with a European Organization for Research
and Treatment of Cancer study investigating the role of
adjuvant perioperative chemotherapy in patients under-
going hepatic resection for colorectal liver metastases.
In this study, 16.4% of the randomized patients in the
control arm (without chemotherapy) did not undergo
planned hepatic resection [31]. This study emphasizes
the fact that chemotherapy is a significant cost driver.
This cost-effectiveness analysis was based on a conserva-
tive approach meaning that not all beneficial effects were
included in the analysis. Additional FDG-PET findings
were divided in extrahepatic disease, evidence of benign
disease, and additional liver disease. In seven patients,
FDG-PET detected additional extrahepatic disease
initially missed on CT scan (lung or mediastinal
metastases in five patients and extensive abdominal
lymph node metastases in two cases). In five patients,
FDG-PET did not show uptake in focal liver lesions,
indicating benign liver disease; additional diagnostics
confirmed this. In 18 patients, FDG-PET showed
additional liver findings discordant with CT. In three of
these patients, FDG-PET predicted extensive central
liver involvement judged resectable on CT. In all three
patients resection was judged impossible at laparotomy
and further surgical treatment was cancelled. In this last
group, FDG-PET correctly predicted futile laparotomies
in 10 patients who were operated on, because of
discordance compared with CT (the leading diagnostic
in our study). Those 10 operations could have increased
the nonchemotherapy costs of the PET group.
The results of this study showed that futile laparotomies
were avoided; therefore, the main economic benefits of
adding FDG-PET to the diagnostic work-up would be
logistical, as hospital performance and quality of care
improves because of more effective planning of OR
capacity and unnecessary operations are avoided. This
‘quality benefit’ is not represented in the outcome of our
cost–utility analysis. Overall, this could imply that
hospital performance and management improves because
unnecessary operations are avoided and the use of OR
capacity is optimized.
The results of sensitivity analyses indicate that the costs
of PET could benefit from a better use of occupancy and
suggest that PET scanning should be concentrated in
high-volume centres that are better able to exploit the
economies of scale. When the capacity of PETscanners is
optimally exploited, this results in a more efficient use of
hardware and trained personnel, providing a solid
argument for the centralization of this modality.
In contrast to other studies, no improvement in the
HRQoL, because of the decrease in futile laparotomies,
could be observed in this study. A possible explanation for
this is the fact that 77% of the treated patients in the
CWU group and the 84% patients in the PET group
showed almost identical HRQoL outcomes which could
be because of the timing of the start of chemotherapy.
Patients for whom laparotomy is avoided because of the
addition of FDG-PETare scheduled early for chemother-
apy. This could lead to a relatively early decrease in the
HRQoL compared with the patients who receive
chemotherapy later because of disease recurrence after
an initial hepatic resection, as reported earlier [24].
The main limitations of this paper is that the randomized
clinical trial was carried out in the dawning of the hybrid
PET/CT scanner; therefore, this technology was not
taken into account for cost calculation. When data on this
hybrid scanning become available, the added value of the
application of PET/CT scanners should become more
evident. The next challenge will be to develop imaging
methods for the better assessment of liver involvement,
for example, with hybrid PET/MRI, thus further exploit-
ing innovations in the hybrid scanner technology.
In conclusion, the addition of FDG-PET to the diagnostic
work-up in patients with potentially resectable colorectal
liver metastases results in better patient selection without























Cost-effectiveness plane of additional positron emission tomography
(PET) scan from a health care perspective, without costs for
chemotherapy. QALY, quality-adjusted life-years.
Table 4 Sensitivity analysis with number of PET scans per day in
one centre






PET, positron emission tomography.
aScenario during the trial.
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